Physician profile
Daniel Emina
NPI 1861633786
$3,086.48
in general payments reported to CMS, 2019-2025
21 companies · $600 in 2025
The $600 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $818 · 2020: $38.11 · 2023: $469 · 2024: $1,161 · 2025: $600.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480 · Consulting Fee: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,480.24 |
| Consulting Fee | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $750.00 | 2024 | |
| Abbvie INC. | $435.86 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $361.75 | 2023-2025 | Caplyta |
| Lundbeck LLC | $240.80 | 2019-2025 | Rexulti |
| Corium, LLC | $235.57 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $155.26 | 2019 | |
| Axsome Therapeutics, INC. | $134.41 | 2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $120.57 | 2019 | |
| Supernus Pharmaceuticals, INC. | $86.13 | 2023-2025 | Qelbree |
| Vanda Pharmaceuticals INC. | $85.26 | 2019 | |
| Jazz Pharmaceuticals INC. | $80.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $74.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $72.04 | 2019 | |
| Sunovion Pharmaceuticals INC. | $54.27 | 2019-2020 | |
| Bausch Health US, LLC | $50.33 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $40.33 | 2025 | Cobenfy |
| Shire North American Group INC | $27.04 | 2019 | |
| Lilly USA, LLC | $23.23 | 2025 | Zepbound |
| Neurocrine Biosciences, INC. | $21.06 | 2019 | |
| Adlon Therapeutics L.P. | $18.67 | 2020 | |
| Ironshore Pharmaceuticals INC. | $18.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Emina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.